ASD
Overview


Upcoming Events
Flynn Pharma is committed to the delivery of high quality medical educational events that support the continued development of healthcare professionals - it's our way of helping you to help your patients. Don't miss out. Flynn continues to host a series of educational events and webinars around ASD and other neurodevelopmental disorders that are free for healthcare professionals to attend. Sign up to receive our latest updates.
Autism Spectrum Disorder - Continue Your Journey
We work with leading experts in the field to design meeting programmes that explore key issues in ASD.
50% to 75% of children with neurodevelopmental or phychiatric comorbidities experience paediatric insomnia
Insomnia in Children with ASD: The Aetiological Role of Melatonin
Slenyto® (paediatric prolonged-release melatonin) for:
- treatment of insomnia in children and adolescents aged 2-18 years with Autism Spectrum Disorder (ASD), and/or neurogenetic disorders with aberrant diurnal melatonin secretion and/or nocturnal awakenings, where sleep hygiene measures have been insufficient
- treatment of insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD) where sleep hygiene measures have been insufficient
- significant improvements, over baseline, in total sleep time, sleep initiation (latency) and maintenance, child behaviours (externalising), caregivers’ quality of life and resolution of caregiver sleep disturbance
References
- Diagnostic and Statistical Manual of Mental Disorders, 5th edition: DSM-5. American Psychiatric Association, 2017
- NICE Clinical guideline CG170 Autism spectrum disorder in under 19s: support and management. Published August 2013







